These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8904176)

  • 21. Factor VIIa-tissue factor: functional importance of protein-membrane interactions.
    Morrissey JH; Neuenschwander PF; Huang Q; McCallum CD; Su B; Johnson AE
    Thromb Haemost; 1997 Jul; 78(1):112-6. PubMed ID: 9198138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of beta strand movement into a zymogen-like position does not confer higher activity to coagulation factor VIIa.
    Olsen OH; Nielsen PF; Persson E
    Biochemistry; 2004 Nov; 43(44):14096-103. PubMed ID: 15518559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new automated method for continuous registration of factor VII activation in vitro. Activation is accelerated by the concentration of factor VII and the activity state of the protein.
    Bladbjerg EM; Jespersen J; Gram J
    Scand J Clin Lab Invest; 1994 Nov; 54(7):505-14. PubMed ID: 7863227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis.
    Rossetto V; Spiezia L; Senzolo M; Rodriguez K; Gavasso S; Woodhams B; Simioni P
    Int J Lab Hematol; 2013 Feb; 35(1):101-5. PubMed ID: 22958499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis.
    Bozzini C; Girelli D; Bernardi F; Ferraresi P; Olivieri O; Pinotti M; Martinelli N; Manzato F; Friso S; Villa G; Pizzolo F; Beltrame F; Corrocher R
    Thromb Haemost; 2004 Sep; 92(3):541-9. PubMed ID: 15351850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: insights into mechanism of assembly/disassembly from tissue factor.
    Stone MD; Harvey SB; Martinez MB; Bach RR; Nelsestuen GL
    Biochemistry; 2005 Apr; 44(16):6321-30. PubMed ID: 15835921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors.
    Petersen LC; Elm T; Ezban M; Krogh TN; Karpf DM; Steinø A; Olsen EH; Sørensen BB
    Thromb Haemost; 2009 May; 101(5):818-26. PubMed ID: 19404533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis.
    Spiezia L; Rossetto V; Campello E; Gavasso S; Woodhams B; Tormene D; Simioni P
    Thromb Haemost; 2010 Jun; 103(6):1188-92. PubMed ID: 20431847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa.
    Reuning U; Preissner KT; Müller-Berghaus G
    Thromb Haemost; 1993 Feb; 69(2):197-204. PubMed ID: 8456434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?
    Giansily-Blaizot M; Verdier R; Biron-Adréani C; Schved JF; Bertrand MA; Borg JY; Le Cam-Duchez V; Briquel ME; Chambost H; Pouymayou K; Dutrillaux F; Favier R; Martin-Toutain I; Verdy E; Gay V; Goudemand J; Navarro R; Durin A; d'Oiron R; Lambert T; Pernod G; Barrot C; Peynet J; Bastenaire B; Sie P; Stieltjes N; Torchet MF; de Moerloose P;
    Haematologica; 2004 Jun; 89(6):704-9. PubMed ID: 15194538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coagulation factor VII and inflammatory markers in patients with coronary heart disease.
    Ekström M; Silveira A; Bennermo M; Eriksson P; Tornvall P
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):473-7. PubMed ID: 17581323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activate factor VII.
    Khan MM; Hattori T; Niewiarowski S; Edmunds LH; Colman RW
    Thromb Haemost; 2006 Mar; 95(3):462-8. PubMed ID: 16525574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
    Prasad R; Sen P
    Phys Chem Chem Phys; 2017 Aug; 19(33):22230-22242. PubMed ID: 28799584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of warfarin therapy on activated factor VII clotting activity.
    Lippi G; Montagnana M; Salvagno GL; Poli G; Franchini M; Guidi GC
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):221-4. PubMed ID: 16575262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method.
    Halabian R; Roudkenar MH; Esmaeili NS; Masroori N; Roushandeh AM; Najafabadi AJ
    Vox Sang; 2009 May; 96(4):309-15. PubMed ID: 19175565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure, function, and activation of coagulation factor VII.
    Eigenbrot C
    Curr Protein Pept Sci; 2002 Jun; 3(3):287-99. PubMed ID: 12188897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing and monitoring NovoSeven treatment.
    Hedner U
    Haemostasis; 1996; 26 Suppl 1():102-8. PubMed ID: 8904183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
    Jin J; Perera L; Stafford D; Pedersen L
    J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of Factor VIIa/tissue factor.
    Shirk RA; Vlasuk GP
    Arterioscler Thromb Vasc Biol; 2007 Sep; 27(9):1895-900. PubMed ID: 17600222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.